NCT01534598 2026-02-10
FdCyd and THU for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
9 trialsNCT02664181 2024-09-03
PRECISE
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03233724 2023-05-31
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01479348 2020-06-02
Imaging Study for FdCyd and THU Cancer Treatment
National Institutes of Health Clinical Center (CC)
Phase EARLY_PHASE1 Terminated
NCT02847000 2019-01-09
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT02846935 2019-01-07
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT00077051 2016-12-15
Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)
University of Miami
Phase 1 Completed
NCT01041443 2015-06-08
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
City of Hope Medical Center
Phase 1 Completed
NCT00359606 2015-05-06
5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer
City of Hope Medical Center
Phase 1 Completed